Clinical Trial: Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Inflammation

U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT06812429) titled 'Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Inflammation' on Feb. 01.

Brief Summary: The research aims to understand how a specific type of medication called Sodium-glucose co-transporter 2 (SGLT2) inhibitors affect cardiorenal inflammation.

Study Start Date: May 08, 2024

Study Type: INTERVENTIONAL

Condition: Inflammation

Intervention: DRUG: Dapagliflozin (DAPA)

Participants will receive 10mg of Dapagliflozin per day for three days.

Recruitment Status: RECRUITING

Sponsor: Washington University School of Medicine

Information provided by (Responsible Party): Amanda Verma, Washington University School of Medicine...